Member Info for Vertizea-Sun

I'd like to know whether or not the continuing patients remain on their C5 dosage or will they be bumped up to the C6 2.7 level? Wouldn't it be fantastic news ......to go from non-progression to healing.

"and several patients in cohort 5 and earlier cohorts remain on treatment as their disease has not progressed."

PL:

Early days. AS clearly appointed Shaun Chilton and Consilium to assist the board in negotiations. Fingers crossed for a frantic autumn.

It's worth remembering how other industry's will also apply seriously high valuations to a stunning idea. For example, the Adobe Corporation (Photoshop fame) is bidding $20 billion for design collaboration startup called Figma......recently valued at $330 million and with relatively nominal sales - but comes with massive opportunity and potential.

330 Million to 20 Billion. Reminds me of Vodafone and Mannesmann.

Probably the first step in a very busy H2 2023. Staying on AIM?

Because product names are trial secrets.

It nearly worked!

⛏🅾️Ⓜ️

@tom_the_bomb__

I think it was

@MylesMcNulty

(please correct me if wrong) that once said that #AVCT could stop the AVA6000 trial tomorrow & license out the tech to a number of companies to modify their own drugs & Avacta would be a multi-billion company just off the royalties.

Bump:

Phase1a:

Cohort V delivered Doxorubicin at x2.2 normal levels. Cohorts VI will commence early July (RNS pending) and deliver Doxorubicin at x2.7 normal levels. There may/may not be a need for Cohort VII with Doxorubicin delivered in volumes >x3 normal levels.

Alistair stated during the on-line video presentation that:

“We are seeing therapeutically significant levels of Dox in the tumour biopsies”. To repeat, as Alistair did, “THERAPUTICALLY SIGNIFICANT LEVELS”.

Alistair goes on to say, “we know the levels of doxorubicin required to make the drug work and the levels we are seeing in the biopsies are greater. That’s what we can say factually now”. Alistair goes on to say, “Why the H*ll wouldn’t it work”?

Are the patients told? I don't think so.

Chin up Timster. It's just part of the human condition.....having to live with t*****s.

From what I can understand .... thank you.....that covers it.

Review in 6 months? No chance.

AS just fired the starting gun and the race begins. For Avacta to stay independent and fulfil a Roche type dream will require lots of cash and that must be seen to happen before this Autumn's board meetings.... as management dwell on next year's funding. That cash can only come from license deals (plural) or NASDAQ. Or AVCT gets sold for as little as £2/3B. We'll know by December.

Here's hoping AS can take the opportunity to expand on AVA6K survivor details and the Press are listening.

Indeed a mystery and also that Gervais Williams of Premier Miton appears to be personally bullish about Avacta's potential.

Correction: investing in PM Group shares.

Anyone investing in Premier Miton 5 years ago would have lost 60% of their cash so I'm not surprised there have been redemptions and Premier Miton have been forced to sell down to under 3%.

And Baillie Gifford is not under 3%

Ernest Jones (1913) was the first to construe extreme narcissism, which he called the "God-complex", as a character flaw. He described people with God-complex as being aloof, self-important, overconfident, auto-erotic, inaccessible, self-admiring, and exhibitionistic, with fantasies of omnipotence and omniscience. He observed that these people had a high need for uniqueness

"Very interesting and shrewd appointment by Avacta. "

This man would have been swamped with offers of a NED - following the successfull sale of Clinigen to Triton.

Actually accepting Avacta's offer tells you everything you need to know about their prospects, as Shaun Chilton wasn't going to squander his reputation on the second rate.....Game on.

Shaun Chilton is an incredibly well connected man as can be surmised from the press release issued in February last year when as Group CEO of Clinigen he negotiated its acquisition by Triton:

"Clinigen operates from sites in North America, Europe, Africa and the Asia Pacific and has more than 1,000 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. Clinigen currently works with more than 30 of the top 50 pharmaceutical companies and supplies medicines into more than 120 countries.